Pharmacological inhibitors of cyclin-dependent kinases (Q34866778)

5 August 2017

1 reference

title

Pharmacological inhibitors of cyclin-dependent kinases (English)

1 reference

5 August 2017

1 reference

2

Paul Greengard

1 reference

5 August 2017

3

Laurent Meijer

1 reference

5 August 2017

Marie Knockaert

1

1 reference

5 August 2017

1 September 2002

1 reference

Trends in Pharmacological Sciences

5 August 2017

1 reference

5 August 2017

23

1 reference

5 August 2017

9

1 reference

5 August 2017

417-425

1 reference

Protein kinases--the major drug targets of the twenty-first century?

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

To cycle or not to cycle: a critical decision in cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Designing inhibitors of cyclin-dependent kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Intracellular Targets of Paullones. Identification following affinity purification on immobilized inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Identification of cytosolic aldehyde dehydrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Reprogramming leukemic cells to terminal differentiation by inhibiting specific cyclin-dependent kinases in G1.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Protection of normal proliferating cells against chemotherapy by staurosporine-mediated, selective, and reversible G(1) arrest

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Cyclin-dependent kinase 5 prevents neuronal apoptosis by negative regulation of c-Jun N-terminal kinase 3.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Neurotoxicity induces cleavage of p35 to p25 by calpain

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Cdc2 phosphorylation of nucleolin demarcates mitotic stages and Alzheimer's disease pathology.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloid-induced neuronal death.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Cyclin-dependent kinase-5 (CDK5) and amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Cyclin-dependent kinase 4 and cyclin D1 are required for excitotoxin-induced neuronal cell death in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Calpain-mediated cleavage of the cyclin-dependent kinase-5 activator p39 to p29

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Increased cyclin D1 in vulnerable neurons in the hippocampus after ischaemia and epilepsy: a modulator of in vivo programmed cell death?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Cyclin-dependent kinases as a therapeutic target for stroke.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Cyclin D1 and Cdk4 protein induction in motor neurons after transient spinal cord ischemia in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Mild cerebral ischemia induces loss of cyclin-dependent kinase inhibitors and activation of cell cycle machinery before delayed neuronal cell death.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

The cyclin-dependent kinase inhibitor roscovitine inhibits the transactivating activity and alters the posttranslational modification of herpes simplex virus type 1 ICP0.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Flavopiridol inhibits P-TEFb and blocks HIV-1 replication

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Human papillomavirus type 16 E7 maintains elevated levels of the cdc25A tyrosine phosphatase during deregulation of cell cycle arrest

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Protein kinases as drug targets in parasitic protozoa

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

The cyclin-dependent kinase inhibitor p27Kip1 safeguards against inflammatory injury

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Cell cycle in vasculoproliferative diseases: potential interventions and routes of delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Flavopiridol inhibits smooth muscle cell proliferation in vitro and neointimal formation In vivo after carotid injury in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Overexpression of cdk Inhibitor p16INK4a by adenovirus vector inhibits cardiac hypertrophy in vitro and in vivo: a novel strategy for the gene therapy of cardiac hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Bovine oocytes treated prior to in vitro maturation with a combination of butyrolactone I and roscovitine at low doses maintain a normal developmental capacity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Enhanced survivability of cloned calves derived from roscovitine-treated adult somatic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Cyclin-Dependent Kinase Inhibition by New C-2 Alkynylated Purine Derivatives and Molecular Structure of a CDK2−Inhibitor Complex

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

The cyclin-dependent kinases cdk2 and cdk5 act by a random, anticooperative kinetic mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Structure-based design and protein X-ray analysis of a protein kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

Quinazolines as cyclin dependent kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902071-0

1 reference

7 January 2021

10.1016/S0165-6147(02)02071-0

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12237154